AUTL — Autolus Therapeutics plc

—
Nasdaq · Health Care · Biotechnology · CIK 1730463 ·
Last close
$1.09
Market Cap
$290.12M
52W High
$2.58
52W Low
$1.07
ADV30
2,385,409
Next earnings
2026-11-10
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 41,238,000 23,311,000 -43,535,000 -55,091,000 523,059,000 245,405,000 495,663,000
Jun 2026 45,689,000 25,221,000 -43,838,000 -39,111,000 493,226,000 171,414,000 418,387,000
Mar 2026 26,218,000 1,650,000 -59,513,000 -71,598,000 527,065,000 130,925,000 418,239,000
Dec 2025 24,289,000 -1,041,000 -72,469,000 -90,332,000 589,068,000 104,132,000 410,939,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-176,241,000
Investing CF
$276,586,000
Financing CF
$61,325,000
CapEx
$-17,345,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.93
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,552,552,000
Inventory
$35,015,000
Receivables
$62,247,000
ST Investments
$2,972,000
EBIT TTM
$-210,661,000
Pretax Income TTM
$-256,476,000
Interest Exp TTM
$45,815,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$137,434,000
EBITDA
$-208,422,000
Free Cash Flow
—
Enterprise Value
$460,097,280
Total Cash
$248,376,992
Total Debt
$397,016,000
Shares Out
266,162,540
Trailing EPS
$-0.94
Book Value
$0.10
ROE
-174.9%
ROA
-23.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 75,388,000 -270,544,000 -287,528,000 589,068,000 410,939,000 178,129,000 -283,568,000
Dec 2024 10,120,000 -241,426,000 -220,662,000 782,725,000 355,400,000 427,325,000 -206,271,000
Dec 2023 1,698,000 -175,528,000 -208,383,000 375,381,000 263,907,000 111,474,000 -145,587,000
Dec 2022 6,194,000 -142,893,000 -148,839,000 490,274,000 191,600,000 298,674,000 -112,308,000

TTM Snapshot

Revenues TTM
$117,390,000
NetIncome TTM
$-280,159,000
OpCashFlow TTM
—
Assets (Latest)
$493,226,000
Forward EPS
$-0.60

Max Pain — expiry 2026-12-18

max pain strike: $1.50 · spot: $1.06 · call oi: 2,686 · put oi: 65
Expected Move to 2026-12-18: ±$1.10 (103.77%) — implied range $-0.04 – $2.16 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
AGMB AgomAb Therapeutics NV $291.55M $5.92 —
KYTX Kyverna Therapeutics, Inc. $297.14M $4.70 —
SCTX Scribe Therapeutics, Inc. $298.64M $15.77 —
EDIT Editas Medicine, Inc. $281.67M $1.83 —
AGEN AGENUS INC $280.98M $6.21 —

News headlines (Yahoo Finance, 1h cache)

Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
2026-11-10 21:05 · Yahoo
Autolus Therapeutics Q3 Earnings Call Highlights
2026-11-10 15:15 · Yahoo
Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
2026-11-10 12:00 · Yahoo
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference
2026-11-09 12:15 · Yahoo
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026
2026-11-04 14:15 · Yahoo
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-03 21:45 · Yahoo
Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
2026-10-26 20:15 · Yahoo
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
2026-10-05 15:00 · Yahoo
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
2026-10-05 12:30 · Yahoo
AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black
2026-09-12 10:21 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.